Huifeng Bio-Pharmaceutical Technology Inc. (“Huifeng”) develops, produces and sells plant extracts, pharmaceuticals and pharmaceutical raw materials in mainland China and internationally. Founded in 2000, the Company holds the patent for a highly efficient process to extract rutin, one of a class of plant-derived chemicals called flavonoids, with anti-inflammatory, antioxidant and anticoagulant properties. Other flavonoid or flavonoid-derived Huifeng products include troxerutin, quercetin, ginkgo biloba, diosmin and l-rhamnose. Food, dietary supplement and drug manufacturers buy these products for use as the building blocks of drugs, dietary supplements and as additives in functional foods and beverages.

The Company holds all necessary certifications for international and domestic sales: Their production facilities are ISO9001:2000 certified; and they hold a Chinese Good Manufacturing Practices (GMP) certification as well. In January 2007 the Chinese Ministry of Science and Technology, which regulates raw materials extract producers in China, will begin to restrict unqualified producers’ sales. The Company’s participation in PRC government biopharmaceutical industry initiatives also entitles it to product research and commercialization funding.

The company began trading publicly when it completed a reverse merger in 2005, led by the current management team.